Related references
Note: Only part of the references are listed.HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel et al.
OPHTHALMOLOGY (2020)
Comparison of two different treat-and-extend protocols with aflibercept in wet age-related macular degeneration
Claudia Taipale et al.
ACTA OPHTHALMOLOGICA (2020)
Macular Atrophy in Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study)
Mark C. Gillies et al.
OPHTHALMOLOGY (2020)
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52-and 96-Week Findings from ALTAIR A Randomized Controlled Trial
Masahito Ohji et al.
ADVANCES IN THERAPY (2020)
Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study
Giovanni Staurenghi et al.
BMC OPHTHALMOLOGY (2020)
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease A Randomized Clinical Trial
Peter J. Kertes et al.
JAMA OPHTHALMOLOGY (2020)
Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration
Vuong Nguyen et al.
OPHTHALMOLOGY (2019)
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema BOULEVARD Phase 2 Randomized Trial
Jayashree Sahni et al.
OPHTHALMOLOGY (2019)
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial
Mark C. Gillies et al.
JAMA OPHTHALMOLOGY (2019)
Innovative therapies for neovascular age-related macular degeneration
Hasenin Al-Khersan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Optical coherence tomography angiography characteristics of choroidal neovascularization requiring varied dosing frequencies in treat-and-extend management: An analysis of the AVATAR study
Atsuro Uchida et al.
PLOS ONE (2019)
Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials
Rahul N. Khurana et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen FLUID Study 24-Month Results
Robyn H. Guymer et al.
OPHTHALMOLOGY (2019)
Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease
Peter J. Kertes et al.
OPHTHALMOLOGY (2019)
Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment
Henrik Faatz et al.
BMJ OPEN OPHTHALMOLOGY (2019)
Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen
Peter G. Traine et al.
OPHTHALMOLOGY RETINA (2019)
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Sharon D. Solomon et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)
Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study
J. Cui et al.
EYE (2018)
The Treat-and-Extend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis
Mali Okada et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2018)
The fate of eyes with wet AMD beyond four years of anti-VEGF therapy
Justus G. Garweg et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2018)
Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration
SriniVas R. Sadda et al.
OPHTHALMOLOGY (2018)
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration Results with Ranibizumab from the TREND Study
Rufino Silva et al.
OPHTHALMOLOGY (2018)
Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors
Hemal Mehta et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2018)
TWO YEAR OUTCOMES OF TREAT AND EXTEND INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Daniel Barthelmes et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013-2016. The Fight Retinal Blindness! Project
Daniel Barthelmes et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2018)
Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting
Maria Eleftheriadou et al.
OPHTHALMOLOGY AND THERAPY (2018)
Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial
Charles C. Wykoff et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2018)
Quantitative Evaluation of Choroidal Neovascularization under Pro Re Nata Anti-Vascular Endothelial Growth Factor Therapy with OCT Angiography
Scott M. McClintic et al.
OPHTHALMOLOGY RETINA (2018)
Age-related macular degeneration: using morphological predictors to modify current treatment protocols
Mohammed Ashraf et al.
ACTA OPHTHALMOLOGICA (2018)
Current advances in the treatment of neovascular age-related macular degeneration
Victor M. Villegas et al.
EXPERT OPINION ON DRUG DELIVERY (2017)
Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration
Justus G. Garweg et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2017)
Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Oded Sagiv et al.
OPHTHALMOLOGICA (2017)
Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial
Pravin U. Dugel et al.
OPHTHALMOLOGY (2017)
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
Joel Hanhart et al.
BMC OPHTHALMOLOGY (2017)
Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial
Francis Char Decroos et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2017)
Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol
Oystein Kalsnes Jorstad et al.
ACTA OPHTHALMOLOGICA (2017)
Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration 2-Year Results of the TREX-AMD Study
Charles C. Wykoff et al.
OPHTHALMOLOGY RETINA (2017)
A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Maria Gemenetzi et al.
OPHTHALMOLOGY AND THERAPY (2017)
Atrophy of the macula in the context of its wet, age-related degeneration. An inescapable consequence of anti-VEGF therapy?
J. G. Garweg
OPHTHALMOLOGE (2016)
Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol Two-Year Results
Karina Berg et al.
OPHTHALMOLOGY (2016)
Antie-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease From Bench to Bedside
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2016)
Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration
Rohan W. Essex et al.
OPHTHALMOLOGY (2016)
METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Leah N. Kim et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration
Glenn L. Stoller et al.
JAMA OPHTHALMOLOGY (2016)
Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration
Carl D. Regillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2015)
Defining response to anti-VEGF therapies in neovascular AMD
W. M. Amoaku et al.
EYE (2015)
Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting
E. Boulanger-Scemama et al.
JOURNAL FRANCAIS D OPHTALMOLOGIE (2015)
Scheduled versus Pro Re Nata Dosing in the VIEW Trials
Gisbert Richard et al.
OPHTHALMOLOGY (2015)
Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration TREX-AMD 1-Year Results
Charles C. Wykoff et al.
OPHTHALMOLOGY (2015)
Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol
Karina Berg et al.
OPHTHALMOLOGY (2015)
Treatment of Exudative Age-Related Macular Degeneration with a Designed Ankyrin Repeat Protein that Binds Vascular Endothelial Growth Factor: a Phase I/II Study
Eric H. Souied et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2014)
Suppression of Intraocular Vascular Endothelial Growth Factor During Aflibercept Treatment of Age-Related Macular Degeneration
Sascha Fauser et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration Ninety-Six-Week Results of the VIEW Studies
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2014)
Retinal Pigment Epithelial Cell Loss Assessed by Fundus Autofluorescence Imaging in Neovascular Age-related Macular Degeneration
Nishant Kumar et al.
OPHTHALMOLOGY (2013)
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Soraya Rofagha et al.
OPHTHALMOLOGY (2013)
A 12-MONTH PROSPECTIVE TRIAL OF INJECT AND EXTEND REGIMEN FOR RANIBIZUMAB TREATMENT OF AGE-RELATED MACULAR DEGENERATION
Nicholas Toalster et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine
Robert Finger et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Michael A. Singer et al.
OPHTHALMOLOGY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration
Christina Frennesson et al.
ACTA OPHTHALMOLOGICA (2010)
Predicted biological activity of intravitreal VEGF trap
M. W. Stewart et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2008)
The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration
H. Dadgostar et al.
EYE (2008)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration
PJ Rosenfeld et al.
OPHTHALMIC SURGERY LASERS & IMAGING (2005)
Share Paper
